Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters

Cell Rep. 2022 Apr 19;39(3):110688. doi: 10.1016/j.celrep.2022.110688. Epub 2022 Mar 28.

Abstract

The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant with a surprising number of spike mutations raises concerns about reduced sensitivity of this virus to antibody neutralization and subsequent vaccine breakthrough infections. Here, we infect Moderna mRNA-vaccinated or previously infected hamsters with the Omicron BA.1 variant. While the Moderna mRNA vaccine reduces viral loads in the respiratory tissues upon challenge with an early S-614G isolate, the vaccine efficacy is not as pronounced after infection with the Omicron variant. Previous infection with the early SARS-CoV-2 isolate prevents replication after rechallenge with either virus in the lungs of previously infected hamsters, but the Omicron variant replicates efficiently in nasal turbinate tissue. These results experimentally demonstrate in an animal model that the antigenic changes in the Omicron variant are responsible for vaccine breakthrough and re-infection.

Keywords: BA.1; CP: Microbiology; Omicron; SARS-CoV-2; immunity; previous infection; vaccination.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • COVID-19* / prevention & control
  • Cricetinae
  • Disease Models, Animal
  • Mesocricetus
  • SARS-CoV-2*
  • Vaccination
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Antibodies, Neutralizing
  • Vaccines, Synthetic
  • mRNA Vaccines

Supplementary concepts

  • SARS-CoV-2 variants